NeuroCult™ NS-A Proliferation Kit (Human)

Medium for expansion of human neural stem and progenitor cells

You may notice that your reagent packaging looks slightly different from images displayed here or from previous orders. We are temporarily using alternative bottles for this product. Rest assured that the products themselves and how you should use them have not changed.

NeuroCult™ NS-A Proliferation Kit (Human)

Medium for expansion of human neural stem and progenitor cells

From: 333 USD
Catalog #
(Select a product)
Medium for expansion of human neural stem and progenitor cells
Add to Wish List

What's Included

  • NeuroCult™ NS-A Basal Medium (Human), 450 mL (Catalog #05750)
  • NeuroCult™ Proliferation Supplement (Human), 50 mL (Catalog #05753)
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.

Overview

NeuroCult™ NS-A Proliferation Kit (Human) is a standardized, serum-free basal medium and supplement for the culture of human neural stem and progenitor cells from normal tissues or tumor samples, in the neurosphere or adherent monolayer system. When supplemented with appropriate cytokines, NeuroCult™ NS-A Proliferation Kit (Human) is optimized to maintain human neural stem cells in culture for extended periods of time without the loss of their self-renewal, proliferation, or differentiation potential.

NOTE: Addition of rh EGF (Catalog #78006), rh bFGF (Catalog #78003) and heparin (Catalog #07980) is required.
Subtype
Specialized Media
Cell Type
Brain Tumor Stem Cells, Neural Stem and Progenitor Cells
Species
Human
Application
Cell Culture, Colony Assay, Expansion, Functional Assay, Spheroid Culture, Toxicity Assay
Brand
NeuroCult
Area of Interest
Cancer, Drug Discovery and Toxicity Testing, Neuroscience, Stem Cell Biology
Formulation Category
Serum-Free

Data Figures

Total cell expansion for fetal human telencephalic and cortical cell neurospheres cultured with Complete NeuroCult™ Proliferation Medium (Human) containing rh EGF, rh bFGF and heparin

Figure 1. Total Cell Expansion for Fetal Human Telencephalic and Cortical Cells Cultured as Neurospheres with Complete NeuroCult™ Proliferation Medium (Human) Containing rh EGF, rh bFGF and Heparin

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
05751
Lot #
All
Language
English
Document Type
Technical Manual
Catalog #
05751
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
05751
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
05751
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (130)

Gliomas phenocopy an inborn error of metabolism to drive neuronal activity and tumor growth. K. Abdullah et al. Cell 2026 Sep

Abstract

The metabolic hallmarks of high-grade glioma (HGG) are not fully understood. Human brain tissue metabolomics revealed that the creatine synthesis pathway intermediate guanidinoacetate (GAA) accumulated ∼100-fold in HGGs relative to controls, which was caused by imbalanced activities of enzymes in this pathway. Glioma cells secreted GAA rather than using it to produce creatine, implicating an alternative function. GAA accumulates in GAA N-methyltransferase (GAMT) deficiency, an inborn error of metabolism, and elevates neuronal excitability. Neuronal excitability is also increased in glioma and drives tumor growth through neuron-glioma interactions. We hypothesized that glioma-generated GAA excites surrounding neurons. Indeed, GAA induced neuronal hyperactivity by activating GABAA receptors and causing depolarizing currents in glioma-associated neurons with dysregulated chloride homeostasis. Depleting tumoral GAA decreased electrochemical activity, neuron-glioma interactions, and tumor aggressiveness. Our findings unveil a mechanism linking cancer metabolism with cancer neuroscience and leverage human genetics to nominate GAA synthesis as a target in gliomas.
A novel combinatorial therapeutic strategy using resveratrol and viral oncolysis for diffuse intrinsic pontine glioma: an in vitro study. K. Gourishetti et al. 3 Biotech 2026 Sep

Abstract

UNLABELLED: Pediatric central nervous system (CNS) tumors, specifically Diffuse Midline Gliomas (DMG) are a leading cause of cancer-related deaths in children presenting an unmet need for novel therapeutic development. In this study, we assessed the combined effects of resveratrol (RSV) and the oncolytic herpes simplex virus (oHSV), hrR3 in patient-derived diffuse intrinsic pontine glioma (DIPG) cell lines. RSV or hrR3 monotherapy resulted in a dose- and time-dependent reduction in cell viability. RSV pretreatment followed by hrR3 infection led to a significantly greater reduction in tumor cell viability than monotherapy. RSV pretreatment further enhanced the replication of hrR3, as evidenced by increased viral titers. Mechanistic analysis showed that the combination therapy was associated with reduced phosphorylation of the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signaling pathways, along with increased expression of apoptotic markers, including cleaved caspase-3 and Poly (ADP-ribose) polymerase (PARP). Together these findings indicate that RSV potentiates hrR3-mediated oncolysis in DIPG cells by enhancing viral replication, suppressing survival signaling and promoting apoptosis in DIPG cells in vitro. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13205-026-05029-x.
Integrated Genetic Screening Identifies FEN1 as a Selective Vulnerability and Temozolomide Resistance Mediator in Glioblastoma Stem Cells. B. Brakel et al. Cancer research communications 2026 Oct

Abstract

UNLABELLED: Glioblastoma (GBM) is an aggressive brain tumor characterized by therapy resistance and recurrence. GBM stem cells (GSC) are key drivers of tumor maintenance, therapeutic resistance, and relapse, but targeting them remains clinically elusive due to their overlap with normal neural stem cells (NSC) and a lack of actionable vulnerabilities. To identify selective vulnerabilities in GSCs, we performed genome-wide CRISPR-Cas9 loss-of-function screening across patient-derived GSC models under standard-of-care treatment conditions. We identified flap endonuclease 1 (FEN1), a key enzyme in DNA replication and base excision repair, as an essential gene for GSC survival, with enhanced dependency in the context of temozolomide (TMZ) treatment. Genetic knockdown of FEN1 impaired GSC proliferation and self-renewal and extended survival in a patient-derived xenograft model. Pharmacologic inhibition of FEN1 using a small-molecule inhibitor revealed selective cytotoxicity in highly aggressive and recurrent GBM models while sparing NSCs. Notably, FEN1 inhibition synergized with TMZ to induce DNA double-strand breaks and potentiate cell death only in a subset of GSCs sensitive to FEN1 inhibition. Mechanistically, single-cell transcriptomics revealed that FEN1 expression correlates with programs linked to proliferation, stemness, and DNA damage repair, underscoring its role in maintaining the treatment-refractory phenotype. Our findings identify FEN1 as a selective vulnerability in aggressive, proliferative GSCs. FEN1 inhibition not only impairs GSC viability but also restores sensitivity to TMZ in treatment-resistant models, offering a strategy for salvage therapy in recurrent GBM. These results support the development of FEN1-targeted therapies and lay the foundation for a biomarker-guided approach to overcoming chemoresistance in GBM. SIGNIFICANCE: GBM is a lethal brain tumor driven by therapy-resistant GSCs. We identified FEN1 as a selective vulnerability of GSCs that promotes TMZ resistance. FEN1 inhibition disrupts GSC self-renewal, restores TMZ sensitivity, and spares healthy NSCs, establishing FEN1 as a precision neuro-oncology target.
You may notice that your reagent packaging looks slightly different from images displayed here or from previous orders. We are temporarily using alternative bottles for this product. Rest assured that the products themselves and how you should use them have not changed.